<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686868</url>
  </required_header>
  <id_info>
    <org_study_id>OFA110867</org_study_id>
    <nct_id>NCT00686868</nct_id>
  </id_info>
  <brief_title>Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients</brief_title>
  <official_title>Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will examine the safety and tolerability, PK and PD of subcutaneously administered
      GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose
      escalation/de-escalation phase to investigate the minimal efficacious dose based on PD
      markers with an acceptable safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2008</start_date>
  <completion_date type="Actual">May 2, 2011</completion_date>
  <primary_completion_date type="Actual">March 11, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as described by the incidence and severity of adverse events [AEs], clinical laboratory parameters and vital signs.</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Requirement for the use of pre-medication, including the timing, type and dose required.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine fluorescent activated cell sorting (FACS) analysis.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD parameters including estimation of time to re-population of CD-19 peripheral blood B-cells to above LLQ (and/or &lt;95% depletion) following single subcutaneous dose of Ofatumumab.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as measured by the incidence, titre and type of human anti-human antibody (HAHA) immune response.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pharmacodynamic/biomarkers of disease activity and immune status may include high sensitivity C-reactive protein (hsCRP), Erythrocyte Sedimentation Rate (ESR), B-Lymphocyte Stimulator (BLyS/BAFF), B-Lymphocyte Chemokine (BLC), IL-6,</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulins (IgA, IgG, IgM), Complement (CH50, C3, C4), IgM Rheumatoid Factor (IgM-RF), IgA-RF and IgG-RF, anti-cyclic citrullinated peptide antibody (aCCP),</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum amyloid A (SAA), CD-3+, CD-4+ and CD-8+ lymphocytes or other biomarkers, as data permit.</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (B-cell depletion and re-population) as measured by CD-19 peripheral blood B- lymphocyte count via routine FACS analysis.Other Secondary Endpoints</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofatumumab</intervention_name>
    <description>fully human anti-CD20 monoclonal antibody</description>
    <arm_group_label>30mg</arm_group_label>
    <arm_group_label>3mg</arm_group_label>
    <arm_group_label>60mg</arm_group_label>
    <arm_group_label>0.3mg</arm_group_label>
    <arm_group_label>100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female aged ≥ 18 years

          -  A diagnosis of rheumatoid arthritis according to the American College of Rheumatology
             (ACR1987 classification) of at least six months prior to screening

          -  Subjects must be treated with MTX, 7.5-25 mg/week, for at least 12 weeks prior to
             Visit 2, with the last 4 weeks prior to Day 2 at a stable dosage

          -  Patient must be willing to receive folic acid ≥5mg/wk 4 weeks prior to baseline
             administered according to locally accepted practice

          -  Body mass index (BMI) &lt; 35kg/m2 (inclusive)

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form

        Key Exclusion Criteria:

          -  Subjects with a history of a rheumatic autoimmune disease other than RA (except
             secondary Sjögren's syndrome), or with significant systemic involvement secondary to
             RA (vasculitis, pulmonary fibrosis or Felty's syndrome)

          -  Previous exposure to biologic cell depleting anti-rheumatic therapies, including
             investigational compounds (e.g. anti-CD11a, anti-CD19, anti-CD20, anti-CD22,
             anti-BLyS/BAFF, anti-CD3, anti-CD4, anti-CD5, anti-CD52)

          -  Exposure to etanercept &lt; 4 weeks, infliximab or adalimumab &lt; 8 weeks, or abatacept or
             anakinra &lt; 12 weeks prior to visit 2

          -  Received any of the following treatments within 4 weeks prior to Visit 2:

          -  Anti-cancer therapy (e.g. alkylating agents, anti-metabolites, purine analogues,
             monoclonal antibodies)

          -  Glucocorticoid unless given in doses equivalent to ≤ 10 mg of prednisolone /day

          -  Intra-articular, i.m. or IV corticosteroids

          -  Live/attenuated vaccinations

          -  Cyclosporine

          -  Azathioprine

          -  Penicillamine

          -  Sulfasalazine

          -  Bucillamine

          -  Hydroxychloroquine

          -  Chloroquine

          -  Exposure to leflunomide within 12 weeks prior to visit 2 unless the subject has
             completed peroral cholestyramine treatment

          -  Exposure to gold therapy ≤ 12 weeks prior to Visit 2

          -  Exposure to IV immunogammaglobulins ≤ 24 weeks prior to Visit 2

          -  Past or current malignant melanoma

          -  Chronic or ongoing active infectious disease requiring systemic treatment such as, but
             not limited to, renal infection, chest infection with bronchiectasis, tuberculosis and
             active hepatitis B and C

          -  History of significant cerebrovascular disease

          -  Positive plasma / white cell JC Virus (JCV) PCR (either compartment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Echirolles</city>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/OFA110867?search=study&amp;search_terms=OFA110867#rs</url>
    <description>Results for study OFA110867 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK1841157;</keyword>
  <keyword>rheumatoid arthritis,</keyword>
  <keyword>B-cell depletion</keyword>
  <keyword>anti-CD20 monoclonal antibody,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

